Physician profile
Paul Lapco
NPI 1174587331
$12,528.70
in general payments reported to CMS, 2019-2025
19 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,214 · 2020: $1,309 · 2021: $1,840 · 2022: $1,975 · 2023: $2,314 · 2024: $1,387 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,276 · Travel and Lodging: $759 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,275.99 |
| Travel and Lodging | $759.41 |
| Education | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,366.78 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Fiagon Navigation Unit |
| Aerin Medical INC. | $2,008.73 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,273.65 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,020.58 | 2019-2025 | |
| Medtronic, INC. | $880.12 | 2023-2025 | Propel, Stealthstation S8 Platform, Sinuva |
| Acclarent, INC | $575.48 | 2019-2021 | |
| Optinose US, INC. | $544.12 | 2019-2025 | |
| Intersect Ent, INC. | $456.99 | 2021 | |
| Glaxosmithkline, LLC. | $105.04 | 2021-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Hikma Pharmaceuticals USA | $65.18 | 2023-2024 | Ryaltris |
| Neurent Medical Limited | $24.73 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Horizon Therapeutics Plc | $22.98 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.51 | 2025 | Xhance |
| Olympus America INC. | $17.75 | 2024 | Olympus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.93 | 2023 | |
| Kaleo, INC. | $14.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lapco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.